C P Thakkar And Company (Pharma) Profile
Key Indicators
- Authorised Capital ₹ 6.00 M
as on 16-11-2024
- Paid Up Capital ₹ 6.00 M
as on 16-11-2024
- Company Age 30 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 19.11 Cr
as on 16-11-2024
- Satisfied Charges ₹ 36.46 Cr
as on 16-11-2024
- Revenue -0.95%
(FY 2023)
- Profit -104.14%
(FY 2023)
- Ebitda 71.47%
(FY 2023)
- Net Worth -0.21%
(FY 2023)
- Total Assets 18.24%
(FY 2023)
About C P Thakkar And Company (Pharma)
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 6.00 M and a paid-up capital of Rs 6.00 M.
The company currently has active open charges totaling ₹19.11 Cr. The company has closed loans amounting to ₹36.46 Cr, as per Ministry of Corporate Affairs (MCA) records.
Shailesh Thakkar, Divyesh Thakkar, and Ramesh Thakkar serve as directors at the Company.
- CIN/LLPIN
U74999MH1994PLC080101
- Company No.
080101
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
04 Aug 1994
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at C P Thakkar And Company (Pharma)?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shailesh Thakkar  | Managing Director | 04-Aug-1994 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Divyesh Thakkar | Whole-Time Director | 01-Jul-2015 | Current |
| Ramesh Thakkar | Whole-Time Director | 04-Aug-1994 | Current |
Financial Performance of C P Thakkar And Company (Pharma).
C P Thakkar And Company (Pharma) Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 0.95% decrease. The company also saw a substantial fall in profitability, with a 104.14% decrease in profit. The company's net worth dipped by a decrease of 0.21%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of C P Thakkar And Company (Pharma)?
In 2023, C P Thakkar And Company (Pharma) had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Standard Chartered Bank Creation Date: 27 Oct 2022 | ₹15.41 Cr | Open |
Citi Bank Na Creation Date: 22 Sep 2003 | ₹3.70 Cr | Open |
Others Creation Date: 26 Jul 2018 | ₹1.19 Cr | Satisfied |
How Many Employees Work at C P Thakkar And Company (Pharma)?
Unlock and access historical data on people associated with C P Thakkar And Company (Pharma), such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of C P Thakkar And Company (Pharma), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped C P Thakkar And Company (Pharma)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
